Business
Recruitment of Senior Scientist with Clinical PK/P
Recruitment of Senior Scientist with Clinical PK/P.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 8879U Physiomics PLC 07 January 2013 \n \n\n \nPhysiomics plc\n(\"Physiomics\") or (\"the Company\") \n \n \nRecruitment of Senior Scientist with Clinical PK/PD experience \nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that Dr Hitesh Mistry has joined the Company as a Senior Scientist. \nDr Hitesh Mistry, Clinical PK/PD Modeller, has experience in modelling and simulation in the pharmaceutical industry from target identification (systems biology) to clinical development (population PKPD). His work in early clinical oncology at AstraZeneca, building a translational disease model for Prostate Cancer, culminated in being awarded an AstraZeneca Oncology Innovation Award in 2012. He was also involved in the development and deployment of AstraZeneca's first systems biology/pharmacology project in the cardiac toxicity area. Dr Mistry will lead the development of Physiomics' flagship new product, Virtual Tumour Clinical and will also be involved in developing the company's cardiac toxicity model.\nDr Mark Chadwick, CEO of Physiomics, commented:\n\"We are extremely pleased to welcome Dr Mistry to our team. His unique mix of modelling, clinical and large pharma experience will be invaluable in the development of Virtual Tumour Clinical and for moving our collaborations firmly into the clinical space. This will allow access to a much larger market than the pre-clinical arena in which the Company currently operates.\"\n \n \nEnquiries:\n \nPhysiomics plc \nMark Chadwick \n+44 (0)1865 784980\n \nWH Ireland Limited\nKaty Mitchell\n+44 (0) 161 832 2174\n \n \nAbout Physiomics plc\n \nPhysiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in...